Finerenone cardiovascular and kidney outcomes by age and sex: FIDELITY post hoc analysis of two phase 3, multicentre, double-blind trials

Finerenone cardiovascular and kidney outcomes by age and sex: FIDELITY post hoc analysis of two phase 3, multicentre, double-blind trials

Objectives This study aimed to evaluate the efficacy and safety of finerenone, a selective, non-steroidal mineralocorticoid receptor antagonist, on cardiovascular and kidney outcomes by age and/or sex.Design FIDELITY post hoc analysis; median follow-up of 3 years.Setting FIDELITY: a prespecified ana...

Full description

Bibliographic Details
Main Authors: George L Bakris, Peter Rossing, Stefan D Anker, Gerasimos Filippatos, Bertram Pitt, Shweta Bansal, Maria E F Canziani, Rita Birne, Luis M Ruilope, Alfredo E Farjat, Peter Kolkhof, Andrea Lage, Meike Brinker
Format: Article
Language:English
Published: BMJ Publishing Group 2024-03-01
Series:BMJ Open
Online Access:https://bmjopen.bmj.com/content/14/3/e076444.full

Internet

https://bmjopen.bmj.com/content/14/3/e076444.full

Similar Items